Victoria E R Parker

Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA

Marjorie J. Lindhurst, Victoria E R Parker, Felicity Payne et al. · Nature Genetics · 2012 · 313 citations · Full text

Genome Instability, Somatic Variant, Cell Division +9

Clinical delineation and natural history of the <i>PIK3CA</i>‐related overgrowth spectrum

Kim M. Keppler‐Noreuil, Julie C. Sapp, Marjorie J. Lindhurst et al. · American Journal of Medical Genetics Part A · 2014 · 301 citations · Full text

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Phil Ambery, Victoria E R Parker, Michael Stümvoll et al. · The Lancet · 2018 · 295 citations

Obesity, Metabolic Syndrome, Medicine +7

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist

Victoria E R Parker, Darren Robertson, Tao Wang et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 115 citations · Full text

Hypoinsulinaemic, hypoketotic hypoglycaemia due to mosaic genetic activation of PI3-kinase

Sarah M. Leiter, Victoria E R Parker, Alena Welters et al. · European Journal of Endocrinology · 2017 · 38 citations · Full text